Thymalin
Thymalin (Thymic Peptide Bioregulator)
Natural Thymic Peptide Bioregulator for Immune Support
What is Thymalin?
Thymalin is a natural peptide bioregulator extracted from the thymus glands of young calves. It was developed in the 1970s at the Institute of Gerontology in the former Soviet Union by researchers Vladimir Khavinson and Vyacheslav Morozov, who were investigating the biological basis of immune aging and its connection to overall longevity. Thymalin belongs to a family of short peptide bioregulators that work not as blunt pharmacological agents but as precise regulators of gene expression in target tissues.
The thymus gland is central to the education and maturation of T-lymphocytes, the immune cells responsible for adaptive immunity. With age, the thymus undergoes progressive involution, shrinking in size and reducing its output of naive T-cells. This thymic decline is considered a primary driver of immunosenescence, the gradual deterioration of immune function that makes older individuals more vulnerable to infection, cancer, and autoimmune dysregulation. Thymalin works by supplying the signaling peptides the aging thymus can no longer produce in sufficient quantities.
At the molecular level, thymalin's short peptide sequences bind to double-stranded DNA and histone proteins, modulating gene expression in immune cells. This mechanism supports T-cell differentiation, restores interleukin-2 (IL-2) production, and regulates calcium-driven activation cascades in thymocytes and macrophages. The peptide reduces receptor-mediated and mitochondrial apoptosis in blood lymphocytes, extending their functional lifespan during replicative aging. In effect, it recalibrates the immune system toward a more youthful functional baseline rather than simply stimulating or suppressing it.
Longitudinal research has demonstrated substantial geroprotective effects. Studies in aging populations showed up to a 2-fold reduction in mortality rates for subjects receiving thymalin therapy. A landmark study on COVID-19 in elderly patients, published in 2021, found that thymalin significantly improved immune status markers and clinical outcomes in older patients with severe disease. Thymalin has been clinically used for over 40 years in Russia and Eastern Europe and remains unavailable and unapproved in the United States and European Union.
Research Supply
Source high-purity Thymalin for your research
Dosage Guide
Route: Intramuscular (IM) or subcutaneous (SubQ) injection
Dosing Schedule
| Period | Dose |
|---|---|
| Standard protocol (per cycle) | 10 mg per day for 5-10 consecutive days; repeat every 6 months |
| Maintenance protocol | 5 mg per day for 5 days; repeat every 3-4 months |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|
Cycling Protocol
5-10 consecutive days
3-6 months between cycles
Biannual dosing (every 6 months) is the standard protocol; some maintenance protocols use every 3-4 months at lower doses
Administration Tips
- Thymalin is supplied as a lyophilized powder; reconstitute with sterile water for injection or bacteriostatic water
- Use within 5-7 days of reconstitution when refrigerated
- Do not freeze reconstituted peptide
- Standard protocol based on the Khavinson clinical protocol established through decades of Russian research
Risks & Side Effects
Commonly Reported
Serious Risks
Allergic or hypersensitivity reactions
Rare; may manifest as urticaria, pruritus, or in severe cases, anaphylaxis.
Autoimmune flare
Theoretical risk from broadly enhanced T-cell activity in individuals with pre-existing autoimmune conditions.
Immune dysregulation in lymphoproliferative disorders
Enhanced immune activity may be contraindicated in individuals with lymphoma or leukemia.
Contraindications
- Active autoimmune disease (stimulation of T-cell activity may worsen conditions such as rheumatoid arthritis, lupus, or multiple sclerosis)
- Known allergy to thymus-derived preparations or bovine proteins
- Active lymphoma or leukemia (immune stimulation contraindicated)
- Pregnancy or breastfeeding (no safety data available)
- Concurrent use of immunosuppressant medications (may antagonize therapeutic intent of those drugs)
Frequently Asked Questions
Related Peptides
Experts Covering Thymalin
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Thymalin has not been approved by the FDA for any medical condition. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.